{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Treatment Regimen Holds Promise for Patients With Advanced Bladder Cancer

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Distinguish the significance of the exploration of complete clinical response to chemotherapy for patients with muscle-invasive bladder cancer (MIBC).
  2. Summarize the results of the study, including the safety profile, of the selected treatment regimen.

Learning Outcomes

Seventy-five percent of participants will demonstrate knowledge of recent research suggesting that a combination of chemotherapy and immunotherapy could help preserve quality of life for patients with muscle-invasive bladder cancer (MIBC) by achieving a minimum score of 70% on the posttest.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH
  • NM - BON 1.0 CH
  • SC - BON 1.0 CH
  • WV - BOERN 1.0 CH

Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.













Test Code: OT1123
Published: November 2023
Expires: 9/5/2025
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Catlin Nalley
Topics: Bladder Cancer